Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | SLC25A5 | P05141 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15457517 | 0.77 | ALDH1A1 (1.00) | MAPTALDH1A1KDM4EPOLBTSHR | |
| SCHEMBL9396153 | 0.76 | ALDH1A1 (0.76) | MAPTALDH1A1KDM4EPOLBTSHR | |
| SCHEMBL22402568 | 0.76 | ALDH1A1 (0.96) | MAPTALDH1A1KDM4EPOLBTSHR | |
| SCHEMBL9193723 | 0.75 | ALDH1A1 (0.53) | MAPTALDH1A1KDM4EPOLBTSHR | |
| SCHEMBL1220095 | 0.74 | ALDH1A1 (0.62) | MAPTALDH1A1KDM4EPOLBTSHR | |
| SCHEMBL20634111 | 0.74 | SLC25A5 (0.46) | MAPTALDH1A1KDM4EPOLBTSHR | |
| SCHEMBL1573209 | 0.72 | SLC25A5 (0.47) | MAPTALDH1A1KDM4EPOLBTSHR | |
| SCHEMBL11304206 | 0.71 | ALDH1A1 (0.59) | MAPTALDH1A1KDM4EPOLBTSHR | |
| SCHEMBL313930 | 0.71 | ALDH1A1 (0.59) | MAPTALDH1A1KDM4EPOLBTSHR | |
| SCHEMBL2995240 | 0.70 | SLC25A5 (0.46) | MAPTALDH1A1KDM4EPOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118211740-A | Multi-objective optimization evolution method for time window vehicle path guided by historical information | 国网湖北省电力有限公司宜昌供电公司 | 2024-06-18 | — | — | CN | claimed |
| CN-109873643-B | A/D sampling circuit and sampling method for alternating current power supply resistance type sensor | 上海航嘉电子科技股份有限公司 | 2024-03-22 | — | — | CN | claimed |
| CN-113835984-B | Many-core application performance evaluation method based on domestic super-computing micro-architecture | 山东省计算中心（国家超级计算济南中心） | 2023-08-08 | — | — | CN | claimed |
| WO-2023090935-A1 | METHOD FOR PRODUCING AGM PEPTIDES THAT BIND SPECIFICALLY TO NUCLEOLIN | 애니젠 주식회사 | 2023-05-25 | — | — | WO | claimed |
| WO-2025087148-A9 | COMMUNICATION METHOD AND APPARATUS, AND READABLE STORAGE MEDIUM | 华为技术有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-12578345-B2 | Single molecule peptide sequencing | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-17 | — | — | US | disclosed |
| CN-116068339-B | Power system line fault detection and discrimination method | 山东理工大学 | 2026-02-27 | — | — | CN | disclosed |
| US-12379381-B2 | Single molecule peptide sequencing | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-08-05 | — | — | US | disclosed |
| WO-2025087148-A1 | COMMUNICATION METHOD AND APPARATUS, AND READABLE STORAGE MEDIUM | 华为技术有限公司 | 2025-05-01 | — | — | WO | disclosed |
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | UNIVERSITY OF WASHINGTON | 2025-04-03 | — | — | US | disclosed |
| CN-119557044-A | Design and execution method, equipment and medium of multi-register virtual machine instruction set | 北京握奇数据股份有限公司 | 2025-03-04 | — | — | CN | disclosed |
| US-20250066374-A1 | RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS, AND USES THEREOF | Clarity Pharmaceuticals Ltd (AU) | 2025-02-27 | — | — | US | disclosed |
| EP-0923528-B1 | OLIGOSACCHARIDE SYNTHESIS | ALCHEMIA PTY LTD (AU) | 2002-11-06 | — | — | EP | disclosed |
| US-6462183-B1 | SOLID PHASE OLIGOSACCHARIDE SYNTHESIS | ALCHEMIA PTY LTD (AU) | 2002-10-08 | — | — | US | disclosed |
| EP-0923528-A4 | OLIGOSACCHARIDE SYNTHESIS | ALCHEMIA PTY LTD (AU) | 2000-07-19 | — | — | EP | disclosed |
| EP-0977763-A4 | PROTECTED AMINOSUGARS | ALCHEMIA PTY LTD (AU) | 2000-07-12 | — | — | EP | disclosed |
| EP-0977763-A1 | PROTECTED AMINOSUGARS | Alchemia Pty. Ltd. (AU) | 2000-02-09 | — | — | EP | disclosed |
| EP-0923528-A1 | OLIGOSACCHARIDE SYNTHESIS | Alchemia Pty. Ltd. (AU) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998038197-A1 | PROTECTED AMINOSUGARS | ALCHEMIA PTY. LTD. (AU) | 1998-09-03 | — | — | WO | disclosed |
| WO-1998008799-A1 | OLIGOSACCHARIDE SYNTHESIS | ALCHEMIA PTY. LTD. (AU) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066374-A1 | RADIOPHARMACEUTICALS, RADIOIMAGING AGENTS, AND USES THEREOF | SLC30A5, SLC40A1, FOLH1 | MAPT 4463/4885ALDH1A1 1334/4885KDM4E 1359/4885 |
| US-12379381-B2 | Single molecule peptide sequencing | MICA, ANPEP, DNPEP | MAPT 4022/4885ALDH1A1 4830/4885KDM4E 4572/4885 |
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | DHFR, CCNH, ODC1 | MAPT 2164/4885ALDH1A1 4524/4885KDM4E 2667/4885 |
| US-12578345-B2 | Single molecule peptide sequencing | SET, PTMS, MICA | MAPT 1169/4885ALDH1A1 4795/4885KDM4E 3313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.